Ligand Pharmaceuticals Inc (LGND) bonds
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$1.13B
$448.31M due within a year
Net debt
$1.07B
After $55.96M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
8.7×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2012
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Ligand Pharmaceuticals's 10-Q for the period ended Sep 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| Convertible Senior Notes due 2030 Convertible at $253 a share | 0.75% | 2030 | $460.00M | $460.00M |
| Convertible Senior Notes due 2030 - Initial Purchase Option Convertible | – | 2030 | $60.00M | – |
| Convertible Senior Notes due 2031 Convertible at $334 a share | 0.00% | 2031 | $700.00M | $700.00M |
| Convertible Senior Notes due 2031 - Initial Purchase Option Convertible | – | 2031 | $75.00M | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn |
|---|---|---|---|
| Revolving Credit Facility | $125.00M | – | – |
| Revolving Credit Facility | $125.00M | $124.40M | $0 |
See a number that looks wrong?